security identification display area of a U.S. airport.

EFFECTIVE DATE: January 31, 1996. FOR FURTHER INFORMATION CONTACT: Robert Cammaroto (202–267–7723) or Linda Valencia (202–267–8222).

SUPPLEMENTARY INFORMATION:

Need for Correction

As published, the final regulations contain a minor error which may prove to be misleading and, therefore, in need of correction.

Correction of Publication

Accordingly, the publication, on Tuesday, October 3, 1995, of the Unescorted Access Privilege final rule (FR Doc. 95–24546) is corrected as follows:

§108.33 [Corrected]

On page 51869, in the third column, in § 108.33, paragraph (a)(2), lines 8 and

9, the words "in paragraphs (b)(2) (i) through (xxv) of this section" are corrected to read "in paragraphs (a)(2) (i) through (xxv) of this section".

Donald P. Byrne,

Assistant Chief Counsel, Regulations Division.

[FR Doc. 95–27228 Filed 11–1–95; 8:45 am] BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, 524, 526, 529, and 558

Animal Drugs, Feeds, and Related Products; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the change of sponsor for 62 approved new animal drug applications (NADA's) from SmithKline Beecham Animal Health to Pfizer, Inc.

EFFECTIVE DATE: November 2, 1995. **FOR FURTHER INFORMATION CONTACT:** Benjamin A. Puyot, Center for Veterinary Medicine (HFV–130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–

SUPPLEMENTARY INFORMATION:

1646.

SmithKline Beecham Animal Health, 1600 Paoli Pike, West Chester, PA 19360, has informed FDA that it has transferred the ownership of, and all rights and interests in, the following approved NADA's to Pfizer, Inc., 235 East 42d St., New York, NY 10017.

NADA no.	Drug and species
012–437	Trimeprazine Tartrate Prednisolone (Temaril-p) Tablets-canine
013–201	
014–366	Sodium Liothyronine (Cytobin) Tablets-dog
015–102	Sulfadimethoxine (Albon Tablets) Antibacterial-dog and cat
015–147	Prochlorperazine Édisylate, Isopropamide Iodide (Ďarbazine) Injectable–doç and cat
031–205	Sulfadimethoxine (Albon Agribon 12.5% Drinking Water Solution) Anti- bacterial-chicken, turkey, and cattle
031–715	1 21
031–914	
032–704	
033–760	
035–161	
038–281	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
039–729	, ,
041–245	
043–785	
046–285	
055-042	
055-069	
055-070	, ,
055-074	
055–078	
055–079	, , , , , , , , , , , , , , , , , , , ,
055–080	
055–081	, ,
055–084	
055–085	
055–087	
055–088	, , ,
055–089	, , ,
055–091	
055–095	
055–099	
055–100	
055–101	
091–467	
091–407	
093–107	Suiradimethoxine (Albon Sr Sustained Kelease Bolus)-Cattle

NADA no.	Drug and species
098–431	Tylan 10 (Tylosin) Premix–swine
100–929	Sulfadimethoxine Ormetoprim (Primor Tablets) 100/20, 200/40, 500/100, 1,000/200 mg-dog
104–493	Diethylcarbamazine Citrate (Filaribits) Tablets–dog
108–687	Dexamethasone (Pet-derm III) Tablets-dog
109–722	Oxibendazole (Anthelcide Eq Equipar) Suspension Anthelmintic-horse
110–048	Albendazole (Valbazen 11.36%) Drench Suspension Cattle Anthelmintic-
111–369	Dexamethasone Sterile Solution (Dexamethasone) Injectable–dog, cat, and horse
120–724	Virginiamycin Monensin Roxarsone (Stafac Coban 3-nitro)-poultry
121–042	Oxibendazole (Anthelcide Eq) Paste-horse
122–481	Virginiamycin Monensin (Stafac 10, 44, 110, 500 Coban 45) Premix–poultry
122–608	Virginiamycin Lasalocid (Stafac 22, 44, 110, 500 Avatec) Premix–poultry
122–822	Virginiamycin Amprolium plus Ethopabate (Stafac 22, 44, 110, 500 Amprol) Premix–chicken
125–961	Sodium Chloride, K Phosphate, K Citrate, Citric Acid, Glycine, Dextrose Powder-calves
128–070	Albendazole (Valbazen) Paste Anthelmintic-cattle
128–517	Diethylcarbamazine Citrate (Pet-dec) Tablet-dog
136–483	Diethylcarbamazine Citrate, Oxibendazole (Filaribits Plus) Tablet-dog
138–828	Virginiamycin Salinomycin (Stafac 10, 20, 50, 500 Bio-cox) Premix Coccidiostat–poultry
138–953	Virginiamycin Salinomycin Roxarsone (Stafac Bio-cox 3-nitro) Premix–poultry
140–839	Mupirocin (Bactoderm) Ointment-dog
140–857	Luprostiol (Equestrolin) Injectable Equine-mare
140–862	
140-879	
	4) Ointment-dog and cat
140-893	Epsiprantel (Cestex) Tablets-dog and cat
140–934	Albendazole (Valbazen) Oral Suspension Sheep Anthelmintic-sheep
140–998	Virginiamycin (V-max) Type A Medicated Article Feedlot-cattle

The agency is amending 21 CFR 510.600(c)(1) and (c)(2) to remove the sponsor name for SmithKline Beecham Animal Health because the firm no longer is the holder of any approved NADA's. The agency is also amending 21 CFR parts 520, 522, 524, 526, 529, and 558 to reflect the change of sponsor.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520, 522, 524, 526, and 529

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, 526, 529, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: Secs. 201, 301, 501, 502, 503, 512, 701, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e).

§510.600 [Amended]

2. Section 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications is amended in the table in paragraph (c)(1) by removing the entry for "SmithKline Beecham Animal Health" and in the table in paragraph (c)(2) by removing the entry for "053571".

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 520.45a [Amended]

4. Section 520.45a *Albendazole* suspension is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.45b [Amended]

5. Section 520.45b *Albendazole paste* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.88a [Amended]

6. Section 520.88a Amoxicillin trihydrate film-coated tablets is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.88b [Amended]

7. Section 522.88b *Amoxicillin trihydrate for oral suspension* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.88c [Amended]

8. Section 520.88c *Amoxicillin trihydrate oral suspension* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.88d [Amended]

9. Section 520.88d *Amoxicillin trihydrate soluble powder* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.88e [Amended]

10. Section 520.88e *Amoxicillin trihydrate boluses* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.88g [Amended]

11. Section 520.88g Amoxicillin trihydrate and clavulanate potassium film-coated tablets is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.88h [Amended]

12. Section 520.88h Amoxicillin trihydrate and clavulanate potassium for oral suspension is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§520.90b [Amended]

13. Section 520.90b *Ampicillin trihydrate tablets* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§520.90f [Amended]

14. Section 520.90f *Ampicillin* trihydrate boluses is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§520.540c [Amended]

15. Section 520.540c *Dexamethasone* chewable tablets is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.550 [Amended]

16. Section 520.550 *Dextrose/glycine/electrolyte* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.622c [Amended]

17. Section 520.622c Diethylcarbamazine citrate chewable tablets is amended in paragraph (b)(2) by removing "053571" and adding in its place "000069".

§ 520.623 [Amended]

18. Section 520.623 Diethylcarbamazine citrate, oxibendazole chewable tablets is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.816 [Amended]

19. Section 520.816 *Epsiprantel tablets* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§520.1284 [Amended]

20. Section 520.1284 Sodium liothyronine tablets is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.1638 [Amended]

21. Section 520.1638 *Oxibendazole* paste is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.1640 [Amended]

22. Section 520.1640 *Oxibendazole suspension* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§520.1840 [Amended]

23. Section 520.1840 *Poloxalene* is amended in paragraph (c)(1) and (c)(2) by removing "053571" and adding in its place "000069".

§520.1920 [Amended]

24. Section 520.1920 Prochlorperazine, isopropamide sustained release capsules is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§520.1921 [Amended]

25. Section 520.1921

Prochlorperazine, isopropamide with neomycin sustained-release capsules is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§520.2260a [Amended]

26. Section 520.2260a Sulfamethazine oblets and boluses is amended in paragraph (b)(1) by removing "053501" and adding in its place "000069".

§520.2260b [Amended]

27. Section 520.2260b Sulfamethazine sustained-release boluses is amended in paragraph (b)(1) by removing "053501" and adding in its place "000069".

§ 520.2260c [Amended]

28. Section 520.2260c Sulfamethazine sustained-release tablets is amended in paragraph (a) by removing "053501" and adding in its place "000069".

§520.2604 [Amended]

29. Section 520.2604 *Trimeprazine* tartrate and prednisolone tablets is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 520.2605 [Amended]

30. Section 520.2605 *Trimeprazine* tartrate and prednisolone capsules is amended in paragraph (b) by removing "053571" and adding in its place "000069".

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

31. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 522.88 [Amended]

32. Section 522.88 Sterile amoxicillin trihydrate for suspension is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 522.90a [Amended]

33. Section 522.90a Ampicillin trihydrate sterile suspension is amended in paragraph (b)(1) by removing "053571" and adding in its place "000069".

§ 522.90c [Amended]

34. Section 522.90c *Ampicillin* sodium for aqueous injection is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§522.540 [Amended]

35. Section 522.540 *Dexamethasone injection* is amended in paragraph (d)(2)(i) by removing "053571" and adding in its place "000069".

§522.1290 [Amended]

36. Section 522.1290 *Luprostiol sterile solution* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 522.1920 [Amended]

37. Section 522.1920 *Prochlorperazine, isopropamide for injection* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

38. The authority citation for 21 CFR part 524 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 524.1005 [Amended]

39. Section 524.1005 Furazolidone aerosol powder is amended in paragraph (b)(1) by removing "053501" and adding in its place "000069".

§524.1465 [Amended]

40. Section 524.1465 *Mupirocin ointment* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 524.1580b [Amended]

41. Section 524.1580b *Nitrofurazone ointment* is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§524.1580c [Amended]

42. Section 524.1580c *Nitrofurazone* soluble powder is amended in paragraph

(b) by removing "053571" and adding in its place "000069".

§ 524.1600a [Amended]

43. Section 524.1600a Nystatin, neomycin, thiostrepton, and triamcinolone acetonide ointment is amended in paragraph (b) by removing "053571" and adding in its place "000069".

PART 526—INTRAMAMMARY DOSAGE FORMS

44. The authority citation for 21 CFR part 526 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 526.88 [Amended]

45. Section 526.88 Amoxicillin trihydrate for intramammary infusion is amended in paragraph (b) by removing "05371" and adding in its place "000069".

§ 526.464a [Amended]

46. Section 526.464a *Cloxacillin benzathine for intramammary infusion* is amended in paragraph (d) by removing "053571" and adding in its place "000069".

§ 526.464b [Amended]

47. Section 526.464b *Cloxacillin* benzathine for intramammary infusion, sterile is amended in paragraph (d) by removing "053571" and adding in its place "000069".

§ 526.464c [Amended]

48. Section 526.464c Cloxacillin sodium for intramammary infusion, sterile is amended in paragraph (b) by removing "053571" and adding in its place "000069".

§ 526.464d [Amended]

49. Section 526.464d *Cloxacillin* sodium for intramammary infusion is amended in paragraph (b) by removing "053571" and adding in its place "000069".

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

50. The authority citation for 21 CFR part 529 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 529.2464 [Amended]

51. Section 529.2464 *Ticarcillin* powder is amended in paragraph (b) by removing "053571" and adding in its place "000069".

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

52. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

§ 558.464 [Amended]

53. Section 558.464 *Poloxalene* is amended in paragraph (a)(1) and (a)(2) by removing "053571" and adding in its place "000069".

§ 558.465 [Amended]

54. Section 558.465 *Poloxalene free-choice liquid Type C feed* is amended in paragraph (a) by removing "053571" and adding in its place "000069".

§ 558.635 [Amended]

55. Section 558.635 *Virginiamycin* is amended in paragraph (b)(1) by removing "053571" and adding in its place "000069".

Dated: October 24, 1995.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. [FR Doc. 95–26986 Filed 11–1–95; 8:45 am]

BILLING CODE 4160-01-F

GENERAL SERVICES ADMINISTRATION

41 CFR Part 201-9

RIN 3090-AF72

Amendment to Revise FIRMR Provisions Regarding the Standard and Optional Forms Management Program

AGENCY: Information Technology

Service, GSA. **ACTION:** Final rule.

SUMMARY: This rule amends the Federal Information Resources Management Regulation (FIRMR) to simplify and clarify procedures related to the Standard and Optional Forms Management Program. Current procedures for this Program result in delays in the processing of forms requests, especially requests for exceptions to the use of Standard forms. This rule streamlines these processes and allows agencies to deal directly with the responsible parties regarding the issuance and printing of these forms. The specific changes in this rule include allowing agencies to obtain approval for an exception to the use of Standard forms directly from the promulgating agencies; and giving the promulgating agencies full responsibility for:

certifying their proposed forms comply with applicable laws and regulations, announcing the availability of new or revised Standard forms and providing GSA with an accurate camera ready copy of the forms.

EFFECTIVE DATE: This rule is effective December 4, 1995.

FOR FURTHER INFORMATION CONTACT: R. Stewart Randall, GSA, Office of Information Technology (IT) Policy and Leadership, Center for IT Policy and Regulations Management (KAR), 18th and F Streets, NW., Room 3224, Washington, DC 20405, telephone FTS/Commercial (202) 501–4469 (v) or (202) 501–4469 (tdd).

SUPPLEMENTARY INFORMATION: (1) Part 201-9.202 is amended to delegate additional authority and responsibility to agencies regarding the granting of exceptions to Standard Forms. Currently, the FIRMR requires Federal agencies to submit a request for an exception to a Standard Form directly to GSA. GSA then reviews the exception request for conformance to good forms management practices. However, GSA also forwards the exception request directly to the promulgating agency for the agency's recommendation for approval or disapproval of the exception request. Since GSA and the promulgating agency typically agree on the disposition of an exception request, GSA believes it is more efficient to give promulgating agencies full authority for the exception request process. Accordingly, the requirement in section 201-9.202-1 paragraph (b)(2) for Federal agencies to obtain approval from GSA for exceptions to Standard forms is removed for the FIRMR. Instead, agencies will send their exception requests directly to the agency promulgating the Standard Form.

(2) Agencies typically request to establish standard forms because of a statutory or programmatic requirement. In the past, GSA conducted research to verify a requested form was consistent with the agency's authority and would meet the agency's requirements. GSA now will accept agencies' certification that their new or revised forms requirements are legally required and technically adequate. This change eliminates GSA duplicating work already performed by the agency. Agencies will also be required to announce the availability of their new or revised forms in the Federal Register and provide GSA an accurate camera ready copy of the new or revised form. GSA will no longer verify the accuracy of the camera ready copy. Agencies are given full authority and responsibility to